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Alter intrawnwn IhmmbcQtk therapy was shown IO k 
e6cctiw in achicviy rely cownay npnfkon, the Thmm- 
bcdysb In Myacardial lnbwcdcm (TlMI) I nial dcmonalrvlrJ 
that recombinant li~uc-cypc pbsminogcn aclivalor (n-PA) 
provided n higher epsfusion rate than dii strepmltinwc (I).
Hmmr. \he GISSl-2&wnation~l(2,3) and ISIS3 trials (4) 
rhawd no difercncc in mortalily nmong plienb g&n H-PA. 
rtreptoklnnse and sninrepls~ (anisoylated pbsminogn ¶%p 
tokinae actlvamf wmplcx [APSACJ) wikul innawnme 
heparln. This Anding led son% to conclude that more 1~ 
siw regimens lbat wllicvc pAak?r paleixy wluld he al M 
further bencfil iowwr, @vea the SIKIIQ evidenre that aill 
supposed the early opa anay hypothesis (5). the TlMI 
Imcstigatm set cat in the TIM1 4 trial I” cvvnluole Ihc owa!l 
di+al benefit (and the mechanism “1 buncfit) of IU’” prom- 
ising ow regimeos+fmot-loaded -PA (b) ;md combination 
thoxnbolydc therapy (7)--sod to compare them with thmc of 
sinikn ~“estionr in a much lqcr patient tohart. 
Meihods 
Eliility uibxia. P&cots wcrc wrwncd for cnrolhncnl 
at IS clioiial centers (see .Appcndh). To bc cligiik for stody 
patkipad”“. patients had to cxpcrieno: ixhcmic pain for 
236 min in auocialion with ST scgmcnt clcva6o” ~6.1 mV ill 
“1 kost tw motigooor leads or with new left bundk bunch 
block. ‘Ihe onsc! of pain had IO “cur wilhio h h of phmncd 
initiation of trcatmeot. 
Exclosion criteria wcrc qc PXll ycxs. 4dminimrsi0” of 
B-I-PA for acotc myocardkd infxction within the prcviws ? 
weeks or cdmininratkm of minrcpkw or strcptokinow al any 
time. oml anlicoagulatio”. wman uf childbwiog puaed;d. 
prcvioosiy doamcnlcd left bundle bomoch block. other ~&us 
illncs?. ioabilily to compiy with the proloivl or to giw in- 
fonoed cooscot. pmiuor pmicip&.~n in TILlI 4 and coolw 
k&&ions to Ihromhdytic Ihcnpy. The kwa indodcd a 
bkcdii diicr or gaslminlcstin;ll bl:cdin~ wirhin the prc- 
vioos I2 month< P history of ccebnwaculx dircor at ;my 
time. iododing any 6xm of stroke UT wansicnt irhcmir atlocli: 
a coohrmed blood prcssorc > INil IO mm Hg: scwrc lrilutoa 
within the prcvioos 3 oumthr; or o sigoi6ccot sorgicxl procc- 
dorm. cardiac ~tbclcriza6an or nrdiilmonmy rrruziwdo” 
within the prcvioos 2 weeks. lnformcd mnsrot WON “bmincd 
from each patient in uvxdana with the rcq”ircmmt* uf coch 
hospit& lnfiik&mol Rcvicw Boa-d. 
Eligibk plicols wcr: rtmdomly allccatcd with the use of 
sakd eowlc+xs lo n&c. in doable-blind fashion. ckhcr 
fmot-lo&d n-PA (Actiiasc. Genentcch) given “s a IS-mg 
bolos. a G75-nQq (up I” 56-w) inbsion “vcr .%I mm. 
folkwcd by a US&mg&g (up to 33-m@ infosioo over fJl min 
(6); APSAC (Eminw SmithKlinc Bccchom) 6iwo 8s B 30.II 
bolos over 2 to 5 min: or combination rhrombolyric therapy. 
whiih run&cd of II IFmglmlosofn-PA cod co.75m&g (up 
to S6.m~) infusion over 30 min cod o 2&U bolos of APSAC. 
All paticnu rcccivd immedmtc inwwmous heprrin ther- 
apy (administrrcd ill a S.flMLIU iotmucoow bolos followed by 
a l~IU!h infosiun. which wa ~hcn adjuslcd I” muintrdn an 
activvrcd pnkl rhmmbopl.wIin thnc bctrvcc” I5 “d 2 times 
cootml Iml cod aspirin ([Emtrin. SmithKlinc Bccchumj 
325 mg chewed iouncdiately on enrollment if they wcrc not 
already tckii aspkin, cod 32.5 mg dnily thcrcahcr). In light of 
tic rend& of the TlMl 2 trial (II). prdir”& ah” rcceivcd 
intrawnoos follnved by oral mctoprolul if there wcrc “o 
diition of the trcaling phyxicia”. 
Faticnts “ndenvcnt corowy artcriognphy to wanrio 
pcnq of the infam-related array W min aher the start uf 
thrombolytk thcm~. When possible. ar;criai pateq was also 
dctermincd at 66 and 75 min The arterial sheath lor the 
cathevrizatiun was worcd in place and corooary artcriogra- 
phy IY,X rcpcatcd 18 to 36 h aftcr the start of thmmbo!ytic 
thcnpy (or earlier if Ihc pirlicot experienced ~currcnt ixk- 
emit pain with ST qmcnt elevation). If the inhrct.xlatcd 
zxlc~ ws wcludcd at W min (TIM1 gadc 0 or 1 Row) (1) and 
if curonuy cccltion was mnlirmcd at 120 min. rcsac pcrcc 
tmwus transluminal coronary angiopla~ could be pcrfcmned 
ill the diwcrion of the trzatinn chwkiin. Revasccla~~li”” 
Glh aogqlaty or coomary ar& &poss surgmy was rccom- 
mcndcd unly if sigoilicant oxorrcnt ischcmia developed and 
was purfomwd a~ the diwrction of the treating physician (Ill. 
Radionoclidc perfusion imaging wilh technetium-99m 
hcukir :-mcthux@&otyl konilrik (scstamibi) was performed 
rnllrdinr to a sendcrdii~xi ~rot”c”l (I3 immrdiatcly sftcr 
Lhc Itc I;> .X-h catbtetirio~ and b&c hospital di.&hqc. 
Rca vcnniadar funcdon was ucrsrd by mdiooucliie wo- 
tricoh~r~p’hy b&xc hospital diichnrgc. Tclcphooc followop. 
obrGwd at 6 wccb and I par. n-a onnplctc in 96% of 
pa~icms. Angiog~“m% rcdiunuclidc scaos and clcctnxmdi~ 
gown HI’= imctprctcd e Ihc rc*pcai\e Coax Lnbomtorics, 
ad xosp-xtcd ciini-al end Paints wrc wiwcd by the Mor- 
bidny and Morodity Ckwi6coli”n Cummiltce: “II mtcrpalo- 
tkms end rcviccs wcrc nude rithoot kowlcdgc of tlcament 
wignmcnt. 
St& cad minks The oriman end ooiot was the c”m”a- 
kc cod boiot :‘“nu;llirP&~ ““t&w,” dc6ncd as rhe occur- 
wow of anv of the followine throoeh havital dischow (13): 
dulh (sll&“sc morIalily). kcrc &c&c heart hiok & 
cwdiogcoic shock. lw ejection frxti”~~ (mccsorcd by radio- 
“uclidc wuriculognm as <4U% [or as ~30% for paticntr with 
pnvious myocmdiol infarction]). rcinfarction. TIMI gmdc flow 
c? “I 96 minor I8 to 36 h. rcccchtsion as asscsscd by scstamibi 
imaging. major spootaocoos hcmorrba6c (14) or severe aoa- 
phyloxiir A weighted scorn was ccleulabxi for each patient. BE 
prwiounly &s&cd (13). A scpantc anolyxis of tbsc cod 
points rcueokd that the drlioitio” of ejection tiacdon <4ll% 
for all p~~icnts ws a %mgr predictor of l-yccr mortdlily 
than when cjccd”” frwtion <36C was “cd for palknb with 
prior myueardku infomion (1.5). Thus. a acondary cod poinl 
was !hc unsatisfuctory ootcomc end point using ejection frac- 
don <Xl% for all pilticnts as the dc6”irion of lav ejection 
fraction. 
End pciint L6nitims. Severe wnpstive hccri failure was 
defined as Ihr pnw~cc of riles owr more than holf the lung 
ticI& (161, nod csrdiogenic shock was dctincd cs dcwibcd 
ckewhuru 117): thcx cod “oils had to axor 24 h sftcr the 
start uf administration of the study drug. Rrcuncnl infarction 
iv&, delined as in psviour TIMI trkds (14.18). Reocclosioo at 
hospital discharge as asserscd hy wxtamibi imaging was dc- 
6ned as an increlx of >ylSh in dcfcct size bhvrcn the 1% to 
36-h wmmibi ran and the prchospital disehnrge xa” (12). 
Major humurrha~ was defined “I I) P” intracmnial hemor- 
rhogc. 2) hcmnrrhz.gic pericardirl ta:npooadc. 3) a dccrcasc in 
hemoglobin z.5 ddl or 4) ao absoluu dccrcw in hemotoerit 
~15% (c.s.. 8 hemaocrit level of 40% decreasinS lo Z%). 
with tramfusimts being eoumcd as 1 ddl each (IdI9). A 
dcctcare in hematoxit ttfter cormtory bypass surgery was ttot 
cks+siRcd as II hcmorrh@c event. 
Sample size amsidentla~ aad 6tslYlml annlyuL The 
initial sample size proposed for this study w bawd on a 
power analysis of the primary cattposite end @II. II was 
estimated from the TlMl 2 uperiencc (II) that -37% of 
pimu wwld reach n primmy end tint. Three hundred 
@ients in each of the three tnxtmcnt anm would permit the 
detection of an absnltttc 13% di6crettn 137% to 24% la 33% 
far the t&c trcntment compariro~ (20). After an interim 
matis in Octobx 1992 in which thnw calculations demon- 
w&d that the rwmbination arm &Id be unable to nchkve 
aignilicant improvement over tither ol the other arms. the 
Data and Safety Monitoring Baord rcmmmendd discuttinu- 
ation of the combination arm because of futility (II). At the 
tktte that cnmllment ended. April 34 1993.3S2 psticntswn 
IXtOlkd. 
The st~tisucsl unalysr were carried out in SAS (22) and 
mnsistcd of cbi-squon analysts for eateguric type variablts 
variable frequenetes were the Fisher exact 
Tbc survival analysis con&ted of R Kapbm-Meicr plw and 
stat&.: iis(b u&i, tbi logiank statistii 
the double-blind randomized phac of the trial M shown in 
?Rble I. The three wtms we wll q rtched: w l. -20% 
of palm were rk y&m cf age. Twentygvrtt percent of 
patients were women and 14% of rll patients bad bad a prior 
myacardial &hrctiotx -76% cd patients were white. 12% 
b&k, and 12% Hiiic or another race. The avera@ time 
between the orwet of symptxms and the start of dwblc-blind 
thmmbcdytic therapy was 3 h. similar la findin@ in previous 
uiab (10.18) that enmllcd patients presenting within 6 h. 
Pifty-sevm fxtrmt of patients received imtnwtwtts followd 
by cad bet~adrettergie blockily agnts 011 day I. tt9% received 
intrawtous nitmglyesrin, 19% nxeived imnwnous magnc 
skmt and 4% received anginem.bteomerting enzyme inhI& 
tom: there were no si@vcant diifercnas among tbc treatment 
arms in the pmportion of patients rcceivittS these dnqs. 
~wSlu~mf,ldcwal~~. -ilMl~nle2c~3tImvat9Omin~ 
achieved s@ttiticmtly morr often in n-PA-treated patients 
(BA2% n. 72.9% for those receiving APSAC and 67.7% for 
tirzc rwziviq the combination [r&PA VL APSAC. p = 0.a 
front-loaded MA. n ri6rdfv=uttly higher Pqwticw lhan the 
42.9% for those treated with APSK 4nd U.S’i fcrr them 
receiving the combinalion (ri-PA’A APSAC. p < U.ltI: rl.PA 
ts nmtbinafion. p = 0.02). 
humtcy of the inIaret-related artery (TIM1 6rude 2 ur 3 
-1 6t1 mitt after the start OF thnnnbolvtic rher~ns was 
aehicvcd in 779% of rt-PA-treated oaticnts: this q atencv rate 
was signlticantly higher than the SY.S5 p&ncy r4te rhtcrcd 
with APSAC and the VI.39 rate achkd with cnmhination 
thenpy (r&PA vs. APSAC. p = O.iQ n-PA vs. mmbittatiiut. 
p = 0.03) (Pig. I). TIMI Sradc 3 lluw WJS achkwd ir 46% uf 
pntiettts treated with fmnt-tided n-PA compared to 325% of 
APSAC-treated patients and XI.58 of crrmbinarion-treated 
phns_ 
AI 18 to 3b h. TIMI grz& 3 Rwr VI& similar lunong the 
three 9rotuuz 72.6%. 64X% and 71.(1% br the rt-PA. APSAC 
and e&biuatinn arouu~ resoectivelv (u = NSI TlMl cradc ! 
or 3 Row was al& shtkiu lhc thK’c gn~~ps.~ SY.tG:Y4.35 
and 93.796, respextively (p = NS). Rencehtsion of an initially 
patent artety -&attrad in 9 (S.S%) of I12 n-PA-treated 
pdtientr vetsus 2 (2.2%) of 10.7 APSAC..treated patieYts and 1 
(1.7%) of 6S mmbinaticn-treated patients @t-PA vs. APSAC, 
p = O.&rt-PA vucumbination, p = U.07). All I2 patientswith 
reocelusion undetwent s&sequent coronary an&lasty. which 
was ear&d uut imnwditt!ely in I I of them. The comhinatii of 
TIM1 grade 3 tknv al both 90 min and Itl to 36 h which has 
been temted X&nal thrombolysis,” (IS). wus rignilicantly 
higbar for the rt-PA group (53.7% VS. 36.4% for the APSAC 
group aed 40% for the eornbination group [H-PA vs. APSAC. 
P = 0.01; n-PA vs. mmbination, p = U.65]). 
Rubnspltnl mmplkutinna Tlta in-hospital mortalipr rate 
was lowest in the rt-PA group (2.2% \m 8R% in the APSAC 
group and 7.2% in the combinatioo group [rt-PA vs. APSAC. 
p = O.lQ rt-PA ~8. combination, p = O.@J]) (Table 2). New 
0nW of severe UtngeStivr: heart fadure or Cardiogenic rhoch tu 
well ns reo&uslln by hospital dixharg, .as awxcd by 
sestamibi hoa&, also tended to occu; lcast often in d1.z 
R-F4-heated patients (Table 2). Recurnxtt myouudial infarc- 
tion was not sigrdtirsntly diEerent amq the three groups. 
Renuxcttn& avants. There were no intrxr&d hemcu- 
:hqcs in tis [I-PA group. but one r.lch occurred in the 
APSAC XIJ ~ombinalion groups (Table 3). Major spontanr- 
vu5 hemorrhage axurred in 1.4% of rt-PA-ttented pntients 
verse 3.K :md 4.1%. respectivciy. for patients treated with 
APSAC and the combination. Overall lhe rate of major 
lwmarrhap. including bleeding at instramentcul sites. was 
Icnwzr ill the rl-PA-lrented pilticnts (10.9% vs. 21.6% for the 
APSAC group and 21.6% for the combinntion group [rt-PAvs. 
APSAC. p = IUII; H-PA VS. cotnbinatiun. p = U.tE]). 
Unsatishtctory uttteums When all these etlects were inte- 
gatcd intu the composite end print. patimtts tuz4!ed with 
front-lo&d rt-PA tended to hwc it lww incid<acc of 
any in-hcwpitnl uosatis6wtory outcome Qtl.35b \S 59:; for 
APSAC-lrcated patknts aod 53.6% 6x comhinntktn-treated 
Patiunts) (Tab* 1). Howewr. the diiwence did not aclticv~ 
statistical signilixw (for th2 OvenI! campariwt, p = 0.1% 
n-PA vs. APSAC, p = RIP: rt-PA vs. combinatian, p = 0.06). 
With IISC of the seeondq definition of unaatisfaeuny outcome 
(d&ring low ejetiiotl fmction as <40% 6x all patients).whieh 
ha bw:n Siown to correlate betler with long-term mortality 
(IQ the incidence of wai&ctory outcnme WIS lower in the 
rl-PA-Lrealcd patients (42% vs. 52.4% for the APSAC group 
and 56.73 for the cotnbination group [3-way. p = O.oh: r&PA 
vii. APSAC. p = 0.m: rt-PA vs. combinntion, p = 0.03~). The 
sighted unsutisfaetory outcome score showed a similar non- 
at&tic+ sigttificatt trend fat~rinS R-PA. 
Rwaseuiarl&an prncednres. Comtttuy angiophtsty for n 
persistently occluded infatet-relaled artery at 90 min vaa 
performed in a higher pmporiion of patients receiving combi- 
nation tbnpy (N.fa% ys. 10.9% for the n-PA @up and 15% 
fur the APSAC pnxtp) (Table 4), This difference was largely 
doe 111 the lower YRmin patency nte in the APSAC and 
eumbination groups. Conversely, angioplasQ for TeCUWnt 
is&mitt within the 1st Ill h was pwfonned in a hitier 
pr~purtit~n of rt-PA-tmatcd yatknts. Ovemll. the rote of 
nrtscu!.trL<ation with either attgiophtuty or coronaty artery 
hypas surpay wa similar an;.mg tk three gnwps. 
~wg-term bllmv-up Pntbtttr. treated with rt-PA had a 
lt~~er nntrt;llity rate during I-year foliow-up (fig. 2). At 6 
we&. 2.2% of tt-PA-tmated patients had died (vx 8.8% of 
Ihe APSAC pup and 1.2% of the combmation thenpv gmup 
(r&PA vs. APSAC. p = OM; n-PA n. combhtatiun. p = O.M]) 
(Ttie 2). By life table andysir, mortalii was 5.3% at I year 
for tbc n-PA pp. I I % for the APSAC group and 10.5% for 
the ccmbitmtian therapy gnmp (n-PA KS APSAC, p = am: 
rt-PA vs. wtttbinution, p = 0.13 [log-tank;) (Kg, 2). 
Discussion 
It has long baa pan~ulated that the bend! of thwmbotytis. 
tbenpy br acue mywrditd ittfmctiun rertdu bm early 
rcpcrfurion of the ittfarct~r~!atcd otiety (5.2345). According 
to lhis concept. early rqerfusiam of the acutely occluded 
cumluy Pneiylnmupfs IllC mscade ofcvenR tbrltocrur lcr 
au.~tc myocofdinl infarction rind llmib Le went uf mwcwdid 
ncnmk; cunsequentty. It &creases kit re”trk”My&ction 
and impmws awvival. A thmmbdytii regimen that cstablhher 
repeffwkm more rapidly (is., &ii a hiier rate of early 
ittfwct+clated a”wy pat-) wmdd be expected to improve 
ovcnll 0ulfDllle and swivttl(5,23-26). 
Ptwd.baded *PA. Patients treated with fmnt-baded 
ti-PA bad tltc lowest inc;demx d my tmsrdMry outanttc 
end point compatcd with thl of tbe other two tqlmcns, 
ahho@ this diUerctw between group did not acbkw strtis. 
Ruly Idlvctrtlr(ed mtery wncy. At both the ML and 
9Lbmln time point% &PA Lmonstratcd higher mtcs of rcpcr- 
fusion than did the other tw mgimcnx Frunt-luadcd n-PA 
&icwd nearly 8G% pat‘mcy (IlMI 9cldc 2 or 3 flow) as wly 
as 60 min after the start of drug ;dminbtaliun. in cvntwt to 
Ml% iur APSAC c: iis ~ombim~ion. with simihr immovcmcnt 
at 90 min. ‘Ibis superiority of front-loaded rt-Pj\ in esriy 
achicwmettt uf infatct-rchted artery ptcncy at 9U milt is 
similar to that &wed in tbe GUSTO trial (31). which wd 
strcptokinare and an rt-PA-sttepakina.. comhkwton in 
ploccof APSACand th n-PA-APSACcombin~tion (III).Thc 
liw bcwtit of early repcrfusion. esp&dly TM grxlc 3 
tlow. has ban awciated with sntaltr infarct size (3&Y+. 
impruwd left snlricular function (3UllAI). a lmwr NB of 
rc~~cclosion (X42,43) and. most imp0rta.t. impruvud sunival 
(WI-3537.43.44). Thus, the improwd early achiewmL_t of 
Tlhll grade 3 Sow by fmnt-loaded r&PA mmbined wi!h 
intnwwus hcpwin and ;~spirin pruhohly xccunB for the 
impnnud sun&J ahwvcd in thii trinl mui in the GIJSTO triitl 
(!3.?h). Tbw findings pmvidc further coslimtalion d the 
rarly opca arlcty hypothcxix 
Yurbdlty. Althuugb this rubti@ small trial war 1101 sized 
to detect uhangs in mwt&y. front-loaded rt-PA was a..i- 
stud with ;I trend toxaxl a lower m&lily rate Ihan that 
sxwiatrd with AAAC or unnhinatkm thmmboiytic thtxqq. 
Very low nmrtrdity rater haw ban okwwxl in other angio- 
graphic trkds using front-loaded n-PA, intmwww heparin 
and apirin (28.31). llw use of attgioplaty to help sustain 
infarct-r&ted artery patency in p%icnts who had reoccluninn 
may help to explain the remarkably low mortality rate in the 
rt-PA-treated patiat& as has been noted in a previous report 
(4s). Ciwcrsely, although combination thrombolytic tbcrapy 
was ;.wchted with a lav mtc of reocelurion in this and uthcr 
trials (7..M), its failure to improve early patency nppnrs to 
cqhin its fnilwe to imprwe memll wtcomc or to deerera! 
mortality. These findings arc consistent with the hypothesis 
lhat the cambitmtion of early and sustained infwzt-related 
nnery patency iawciatcdwith the I~st loog-tcrmmortality 
rate (35.46). Fbmlly, the eadicr administration of a thmmbo- 
lytic agent bus alsa been found to dcmase mortality (47-49). 
Thus. prompt administmtion after the uwt of symptoms (on 
swrqe by 3 h in this study) of il thmmbolytic regimen such as 
F~~nt-l~IwJ It-PA. shiih further speeds the achievement nf 
npxfusiun, could be expected to lwc nddidw effwts in 
improving sumiwl (50.51). 
Limitatkmr of the scndy. .%xr;ll limitations of this trial 
should bc mnsidcrcd. First, the overall number d paticntr 
cnrolkd in the trial WIN smaller than the planned sample size, 
thereby limiting the paver of the trial Semnd thts was .a~ 
attgiogapbic t&l and it i% possible that the protocol dcrign 
influenced the results, notably in the availability and usz of 
revaswlar~tiot~ prcadurcr. fatly, the mnclusi~~ on mar- 
tality must bc cmridemi in the context of rhc small number of 
dcatbs itI de trial. Howcvcr. both tb qicgmpbic and tbe 
diiiml resulb M consistent with those of the larger GUSTG 
trial (ICUI), thereby knding wpport to the results in this trial. 
Collverscly. this trial was duubk-bliid 4!ereby diminkhii 
any pwsiik bias by physicians caring for the patient& rhfcb 
swvcs to support tbc results of the uttbbmlcd GUSTG trfal 
Cmtclualoas. Fmnt-loadcd al-PA acbii infBrct-&lcd 
awry patency in ~tcllrly 80% of pattents tier bD zaitt, a rate 
sigailicsntty btter than that aociatcd with ABAC or an- 
binstion thmmbolytic therapy. Furthcmmre, early repcrfusim 
with front-loaded H-PA was awciatcd witb trends tawprd 
impnmd meraIl clinical bmctit and l-year rutvival. Iher 
Rndiw strongly support the early open artery bypothrsih and 
they suggest hat titrtbcr impmvmtene in otttmme of patients 
with acute rnyoeardial infarction migltt be adtiicdwith more 
dlcetiw thmmludyiic-antitbmmbotic @men! (18) that im- 
prow early (uru: sustteincd) infarc-related artery patcnry. 
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